{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:52:15Z","timestamp":1790232735962,"version":"4.1.0"},"reference-count":32,"publisher":"American Society for Microbiology","issue":"9","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences, Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2020,8,20]]},"abstract":"<jats:p>\n            This study summarizes drug resistance analyses in 4 recent phase 2b trials of the respiratory syncytial virus (RSV) fusion inhibitor presatovir in naturally infected adults. Adult hematopoietic cell transplant (HCT) recipients, lung transplant recipients, or hospitalized patients with naturally acquired, laboratory-confirmed RSV infection were enrolled in 4 randomized, double-blind, placebo-controlled studies with study-specific presatovir dosing. Full-length RSV\n            <jats:italic>F<\/jats:italic>\n            sequences amplified from nasal swabs obtained at baseline and postbaseline were analyzed by population sequencing.\n          <\/jats:p>","DOI":"10.1128\/aac.02312-19","type":"journal-article","created":{"date-parts":[[2020,2,17]],"date-time":"2020-02-17T13:14:08Z","timestamp":1581945248000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":29,"title":["Assessment of Drug Resistance during Phase 2b Clinical Trials of Presatovir in Adults Naturally Infected with Respiratory Syncytial Virus"],"prefix":"10.1128","volume":"64","author":[{"given":"Danielle P.","family":"Porter","sequence":"first","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Guo","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Perry","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Gossage","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy R.","family":"Watkins","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason W.","family":"Chien","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Jordan","sequence":"additional","affiliation":[{"name":"Gilead Sciences, Inc., Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/22.5.778"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200310-1359OC"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043951"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.2.179"},{"key":"e_1_3_2_6_2","volume-title":"Virazole (ribavirin for inhalation solution, USP). Full prescribing information","author":"Valeant Pharmaceuticals","year":"2016","unstructured":"Valeant Pharmaceuticals. 2016. Virazole (ribavirin for inhalation solution, USP). Full prescribing information. Valeant Pharmaceuticals North America LLC, Bridgewater, NJ."},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1996.02170340056011"},{"key":"e_1_3_2_8_2","volume-title":"Synagix (palivizumab) injection, for intramuscular use. Full prescribing information","author":"MedImmune, LLC","year":"2018","unstructured":"MedImmune, LLC. May 2018. Synagix (palivizumab) injection, for intramuscular use. Full prescribing information. MedImmune, LLC, Gaithersburg, MD. https:\/\/www.azpicentral.com\/synagis\/synagis.pdf."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1086\/521912"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2014-1665"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401184"},{"key":"e_1_3_2_12_2","first-page":"A4457","article-title":"A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults","volume":"197","author":"Hanfelt-Goade D","year":"2018","unstructured":"Hanfelt-Goade D, Maimon N, Nimer A, Riviere F, Catherinot E, Ison M, Jeong SH, Walsh E, Gafter-Gvili A, Nama SR, Napora P, Chowers M, Bergeron A, Zeltser D, Moudgil H, Limaye AP, Couturaud F, Nseir W, McKevitt M, Porter D, Jordan R, Guo Y, German P, Watkins TR, Gossage DL, Chien JW, Falsey AR. 2018. A phase 2b, randomized, double-blind, placebo-controlled trial of presatovir (GS-5806), a novel oral RSV fusion inhibitor, for the treatment of respiratory syncytial virus (RSV) in hospitalized adults. Am J Respir Crit Care Med 197:A4457.","journal-title":"Am J Respir Crit Care Med"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1073"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa028"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1166"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2018.01.375"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz1167"},{"key":"e_1_3_2_18_2","doi-asserted-by":"crossref","unstructured":"Porter D Guo Y Perry J Gossage D Watkins T Chien J Jordan R. 2018. Combined resistance anayses from phase 2b studies of presatovir treatment in RSV-infected adults. abstr 1646. IDWeek 2018 San Francisco CA 3 to 7 October 2018.","DOI":"10.1093\/ofid\/ofy209.116"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0042-6822(03)00115-6"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0175792"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.1982"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit038"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12534"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1086\/508777"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1086\/651605"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181de9d24"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz418"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz472"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2511.190757"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1405198111"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00345-10"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.48.2.413-422.2004"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0910108106"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02312-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02312-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T21:59:56Z","timestamp":1645480796000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02312-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,8,20]]}},"alternative-id":["10.1128\/AAC.02312-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.02312-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2019-11-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02312-19"}}